Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:16 AM ET 8-K
Clinical Trial Data CG Oncology, Inc. CGON

CG Oncology Clinical Trial Data

CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.

8:16 AM ET 8-K
Investor Presentation Acnb Corp ACNB

Acnb Investor Presentation

ACNB Corporation has furnished a formal investor presentation deck for the third quarter of 2026. The presentation provides strategic highlights and financial data for the company and its subsidiaries, ACNB Bank and ACNB Insurance Services, to be used in meetings with investors and analysts.

8:15 AM ET 10-Q
Financial Results Tancheng Group Co., Ltd. QSJC

Tancheng Group Co Q3 2026 Results: Net Loss of $89.7K, Loss Widens

Tancheng Group Co., Ltd. reported zero revenue for the nine months ended September 30, 2026, as it pivoted from product sales to the development of a cultural tourism project. The company recorded a net loss of $338,896 for the period and maintains a significant accumulated deficit of $2.4 million, raising concerns about its ability to continue as a going concern.

Key figure
Net loss $89.7K
8:13 AM ET 8-K
Financial Results Dawson Geophysical Co DWSN

Dawson Geophysical Financial Results

Dawson Geophysical reported third quarter 2026 financial results, including fee revenue of $10.8 million and a net loss of $5.2 million. The company noted that two large channel crew jobs were delayed from Q3 into Q4 due to government permitting issues, but highlighted a strengthened backlog and renewed demand for seismic data acquisition in North America.

“Although our financial performance fell short of our expectations in the third quarter, I cannot be more excited about how this Company is positioned to capitalize on the renewed demand for seismic data acquisition services in North America. We are observing increased demand in Canada and in the United States across the oil and gas space and in other non-traditional markets, such as Carbon Capture, Utilization, and Storage (“CCUS”) and geothermal, and we are scheduled to start our first geothermal data acquisition in November.”

Tony Clark, Dawson’s President and CEO

“I evaluate the Company’s performance over the long term rather than quarterly, and 2026 will be the third year in a row of increasing top-line revenue, improved gross margins and higher Adjusted EBITDA, and I expect that to continue in 2027.”

Tony Clark, Dawson’s President and CEO
8:13 AM ET 10-Q
Financial Results Idaho Strategic Resources, Inc. IDR

Idaho Strategic Resources Q3 2026 Results: Net Income $2.64M, Down 11.2% YoY

Idaho Strategic Resources reported a significant increase in nine-month revenue to $37.1 million in 2026, up from $27.8 million in 2025, driven by product sales. Net income attributable to the company rose to $12.7 million for the nine-month period, while the company transitioned its investment strategy by transferring $64.2 million of US treasury notes from held-to-maturity to available-for-sale.

Key figure
Net income $2.64M · -11.2% YoY
8:13 AM ET 8-K
Financial Results Veritone, Inc. VERI

Veritone Financial Results

Veritone reported Q3 2026 revenue of $18.6 million, a 30% year-over-year decrease, and a net loss of $19.2 million. Alongside results, the company announced a debt exchange for $38.7 million of convertible notes and a $40 million senior secured term loan commitment from Blue Torch Capital to improve its liquidity position.

Term
Q3 2026

“We have spent the majority of fiscal 2026 taking actions to put Veritone in a stronger financial and operational position. With our newly announced convertible notes exchange and commitment letter, combined with our recent cost reduction efforts, we are on a clear path to greatly improve our financial position and ability to execute our operating model and product strategy.”

Ryan Steelberg, President and Chief Executive Officer of Veritone
8:13 AM ET 8-K
Loan & Debt Akebia Therapeutics, Inc. AKBA

Akebia Therapeutics $140M Debt Financing with Symbiotic Capital Opportunities Holding, L.P.

Akebia Therapeutics entered into a $140 million senior secured term loan facility with Symbiotic Capital, consisting of a $60 million initial tranche and $80 million in discretionary tranches. The company used the initial proceeds to repay its existing $55 million debt facility with BlackRock (Kreos). The new facility features a 60-month interest-only period with a maturity date of November 12, 2031.

Value
$140M
Counterparty
Symbiotic Capital Opportunities Holding, L.P.
Term
5 years
8:11 AM ET 8-K
Capital Raise Surrozen, Inc. SRZN

Surrozen Capital Raise of $60M

Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.

Value
$60M
Counterparty
Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
8:11 AM ET 8-K
Financial Results Alx Oncology Holdings Inc ALXO

Alx Oncology Holdings Financial Results

ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology
8:11 AM ET 10-Q
Financial Results Apnimed, Inc. APMD

Apnimed Q3 2026 Results: Net Loss of $29.5M, Loss Widens

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.

Key figure
Net loss $29.5M
8:10 AM ET 8-K
Clinical Trial Data Corbus Pharmaceuticals Holdings, Inc. CRBP

Corbus Pharmaceuticals Holdings Clinical Trial Data

Corbus Pharmaceuticals announced positive Phase 1b clinical trial data for CRB-913, an oral non-incretin therapy for obesity, presented at ObesityWeek 2026. The CANYON-1 trial demonstrated statistically significant weight loss across all doses, with the 60 mg cohort achieving a 5% mean weight loss at 12 weeks and a favorable safety profile with low discontinuation rates.

Term
16 weeks

“In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
8:09 AM ET Form 4
Insider Buying Csquare, Inc. CSQR

Csquare Insider Terri Pizzuto Buys $33.9K of Stock

Terri Pizzuto bought 2,000 shares of Csquare, Inc. at $16.96 a share, worth $33.9K in total on Nov 13, 2026. Shares held after the trade: 5,600 (+55.6%).

Value
$33.9K
Shares
2,000
Price
$16.96
Holding change
+55.6%
Trade date
Nov 13, 2026
8:09 AM ET 8-K
Stock Buyback News Corp NWSA

News Stock Buyback Update

News Corp provided a daily update on its existing $1 billion stock repurchase program as required by Australian Securities Exchange (ASX) rules. The filing includes daily buy-back notifications for the company's Nasdaq-listed Class A and Class B common stock. No ASX-listed CDIs are being repurchased under this program.

8:09 AM ET 8-K
Contract Win Corvex, Inc. MOVE

Corvex Wins $103M Contract from scaled AI inference platform

Corvex, Inc. signed a definitive three-year, $103 million take-or-pay agreement to provide NVIDIA Blackwell computing capacity to a scaled AI inference platform. The deployment, which includes over 1,000 NVIDIA HGX B200 GPUs, is expected to cost $78 million and will be funded primarily through a $26 million customer prepayment and $38 million in non-recourse debt financing.

Value
$103M
Counterparty
scaled AI inference platform
Term
3 years
8:09 AM ET 8-K
Financial Results Iambic Therapeutics, Inc. IAM

Iambic Therapeutics Financial Results

Iambic Therapeutics reported third quarter 2026 financial results, highlighting a pro-forma cash position of $455 million following its IPO and upfront payments from AbbVie. The company reported year-to-date collaboration revenue of approximately $24 million and total operating expenses of $108 million. Key operational milestones included the launch of its Enchant v3 AI model and positive Phase 1/2 data for its HER2 inhibitor, IAM1363.

Term
Q3 2026

“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business. At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval. We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind. We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships. Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”

Tom Miller, PhD, Co-Founder & CEO of Iambic
8:06 AM ET 8-K
Business Update DeFi Development Corp. DFDV

DeFi Development Business Update

DeFi Development Corp. reported its tenth consecutive week of SOL treasury growth, adding 9,482 SOL and SOL equivalents to reach a total of 2,619,311 holdings. The company also highlighted that its Variable Rate Series C Perpetual Preferred Stock (CHAD) has completed 31 consecutive business days of dividend payments at a 14.00% annual rate.

8:06 AM ET 8-K
Leadership Change LKQ Corp LKQ

LKQ Leadership Change

John Meyne, Senior Vice President and President of North America, will retire effective December 31, 2026. Paul Shaw, currently the segment's SVP of Operations and a 25-year veteran of the company, has been appointed to succeed him effective January 1, 2027.

8:06 AM ET 10-Q
Financial Results International Battery Metals Ltd. IBATF

International Battery Metals Q2 2026 Results: Net Income $2.17M, Down 27.2% YoY

International Battery Metals Ltd. reported a net income of $2.14 million for the six months ended September 30, 2026, primarily driven by a $7.93 million non-cash gain from the change in fair value of warrant liabilities. Despite the net profit, the company experienced an operating loss of $5.78 million and negative cash flow from operations as it continues to market its modular direct lithium extraction (MDLE) technology.

Key figure
Net income $2.17M · -27.2% YoY
8:06 AM ET 10-Q
Financial Results Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Q3 2026 Results: Net Loss of $144M, Loss Widens

Jasper Therapeutics reported a significant net loss of $148.4 million for the nine months ended September 30, 2026, primarily driven by a $129.5 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity through a financing and acquisition, ending the period with $135.3 million in cash and cash equivalents.

Key figure
Net loss $144M
8:06 AM ET 8-K
Financial Results International Battery Metals Ltd. IBATF

International Battery Metals Financial Results

International Battery Metals reported Q2 fiscal 2027 results, including a net income of $2.2 million driven by a $5.0 million gain in the fair value of warrant liabilities. The company announced plans to build a compact, transportable pilot plant to provide field data for North American resource owners and expects to secure a $12.0 million bridge loan from its largest investor.

Term
Q2 2027

“We continue to evaluate opportunities across North America, including through an active laboratory testing program. Our ongoing discussions with North American resource owners have made clear that one of their biggest challenges is they need field data from their own resources before making investment decisions. To meet that need, we have begun engineering a compact pilot plant that can be deployed at sites quickly, and at a lower cost than our existing demonstration plant.”

Don Bender, Interim Chief Executive Officer
8:06 AM ET 8-K
Other 8-K Filing Our Bond, Inc. OBAI

Our Bond Other 8-K Filing

Our Bond, Inc. entered into agreements to convert Series B Preferred Stock with a total stated value of $13.26 million into 6,532,640 shares of common stock at a conversion price of $2.03 per share. The transaction reduces the company's total outstanding preferred liquidation preference from approximately $20.9 million to $7.6 million. Participating holders, including the CEO and an independent director, are subject to a six-month lock-up period followed by volume-based resale restrictions.

8:05 AM ET 10-Q
Financial Results Adagio Medical Holdings, Inc. ADGM

Adagio Medical Holdings Q3 2026 Results: Turns Profitable, Net Income $17.8M

Adagio Medical Holdings, Inc. reported a significant decrease in cash and cash equivalents from $17.1 million at the end of 2025 to $3.1 million as of September 30, 2026. The company highlighted substantial risks regarding its ability to continue as a going concern and is exploring strategic alternatives to maximize stockholder value.

Key figure
Net income $17.8M
8:05 AM ET 8-K
Financial Results Apnimed, Inc. APMD

Apnimed Financial Results

Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.

“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”

Kevin Lind, Chief Executive Officer of Apnimed
8:04 AM ET 8-K/A
Financial Results Accelevation Holdings Corp. ACCV

Accelevation Holdings Financial Results

Accelevation Holdings Corp. reported Q3 2026 financial results with revenue growing 66% year-over-year to $202.2 million and a significant bookings increase of 364%. The company also issued an amendment to correct errors in its original earnings release regarding SG&A margins and Adjusted SG&A calculations.

“At Accelevation, we design, manufacture, and install mission-critical infrastructure for customers who rely on our speed and certainty of delivery, and our third quarter results reflect the strength of our operating model and underlying markets.”

Michael Rubiera, Co-Founder and Chief Executive Officer

“We delivered strong growth, profitability, and cash generation in the quarter. Revenue increased more than 60%, bookings grew more than 350%, backlog rose to approximately $1.7 billion, and Adjusted EBITDA margins approached 19% following a weaker first half of the year.”

Ken Krause, Chief Financial Officer
8:04 AM ET 8-K
Business Update Neumora Therapeutics, Inc. NMRA

Neumora Therapeutics Business Update

Neumora Therapeutics reported third quarter 2026 financial results and provided a pipeline update, including the submission of an IND application for NMRA-215 in obesity. The company reported a cash position of $85.7 million and noted that it will require substantial additional funding to continue operations and complete product development.

8:03 AM ET 8-K
Financial Results Adagio Medical Holdings, Inc. ADGM

Adagio Medical Holdings Financial Results

Adagio Medical reported Q3 2026 financial results, highlighting a net income of $17.8 million primarily driven by a $23.0 million gain from the change in fair value of warrant liabilities. The company also announced that its Board of Directors has initiated a formal process to explore strategic alternatives to maximize shareholder value while continuing clinical progress on its vCLAS Ultra System.

Term
Q3 2026

“The third quarter was defined by progress in the clinical and regulatory programs that we believe are the foundation for the value of Adagio and our ULTA platform. Our PMA application for the vCLAS Ventricular Ablation System remains under FDA review, and we initiated the vCLAS Ultra IDE study, which builds on the FULCRUM-VT results with a faster, more maneuverable next-generation catheter.”

Todd Usen, Chief Executive Officer of Adagio Medical

“As the Board’s review of strategic alternatives continues, we have aligned our cost structure around these prioritized programs and remain focused on maximizing value for our shareholders.”

Todd Usen, Chief Executive Officer of Adagio Medical
8:02 AM ET 10-Q
Financial Results Suncrete, Inc. RMIX

Suncrete Q3 2026 Results: Net Income $78K, Down 98.3% YoY

Suncrete, Inc. reported a significant revenue increase to $300.0 million for the nine months ended September 30, 2026, compared to $130.8 million in the prior year, driven by acquisition activity. However, the company realized a net loss attributable to common stockholders of $55.0 million for the period, primarily due to higher interest expenses and substantial acquisition-related costs.

Key figure
Net income $78K · -98.3% YoY
8:02 AM ET 10-Q
Financial Results Montauk Renewables, Inc. MNTK

Montauk Renewables Q3 2026 Results: Net Income $2.14M, Down 58.9% YoY

Montauk Renewables reported total operating revenues of $150.6 million for the nine months ended September 30, 2026, up from $133.0 million in the prior year. The company achieved a net income of $2.37 million for the period, recovering from a net loss of $0.75 million in 2025, despite an operating loss of $2.6 million driven by higher operating and maintenance expenses.

Key figure
Net income $2.14M · -58.9% YoY
8:02 AM ET Form 4
Insider Buying Abeona Therapeutics Inc. ABEO

Abeona Therapeutics Insider Faith L. Charles Buys $34.3K of Stock

Faith L. Charles bought 15,000 shares of Abeona Therapeutics Inc. at $2.29 a share, worth $34.3K in total on Nov 13, 2026. Shares held after the trade: 191,407 (+8.5%).

Value
$34.3K
Shares
15,000
Price
$2.29
Holding change
+8.5%
Trade date
Nov 13, 2026
8:01 AM ET 8-K
Leadership Change Digimarc Corp DMRC

Digimarc Leadership Change

Digimarc entered into a cooperation agreement with its largest shareholder, Ocho Investments LLC, resulting in a significant board refreshment. The company appointed three new directors (Andris Upitis, Kevin McConnell, and Amy O’Keefe) while announcing the upcoming retirement of four current directors by year-end 2026.

Counterparty
Ocho Investments LLC
Term
through Dec 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.